Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Gross Margin (2016 - 2025)

Historic Gross Margin for BioRestorative Therapies (BRTX) over the last 9 years, with Q3 2025 value amounting to 10.42%.

  • BioRestorative Therapies' Gross Margin fell 817700.0% to 10.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.34%, marking a year-over-year decrease of 1000.0%. This contributed to the annual value of 93.0% for FY2024, which is 70000.0% down from last year.
  • BioRestorative Therapies' Gross Margin amounted to 10.42% in Q3 2025, which was down 817700.0% from 97.12% recorded in Q2 2025.
  • BioRestorative Therapies' Gross Margin's 5-year high stood at 100.0% during Q2 2023, with a 5-year trough of 10.42% in Q3 2025.
  • In the last 3 years, BioRestorative Therapies' Gross Margin had a median value of 94.92% in 2024 and averaged 87.31%.
  • Data for BioRestorative Therapies' Gross Margin shows a peak YoY increase of 44100bps (in 2025) and a maximum YoY decrease of -817700bps (in 2025) over the last 5 years.
  • BioRestorative Therapies' Gross Margin (Quarter) stood at 100.0% in 2023, then decreased by -8bps to 92.29% in 2024, then tumbled by -89bps to 10.42% in 2025.
  • Its Gross Margin was 10.42% in Q3 2025, compared to 97.12% in Q2 2025 and 88.36% in Q1 2025.